Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 16 Nov 2026
Standard addition

[Efficacy and safety of hydromorphone hydrochloride extended-release tablets in patients with moderate-to-severe chronic cancer pain: a multicenter, double-blind, non-inferiority randomized controlled trial].

Once-daily hydromorphone extended-release works as well as twice-daily oxycodone for cancer pain, simplifying medication schedules for patients.

This PubMed record examines [Efficacy and safety of hydromorphone hydrochloride extended-release tablets in patients with moderate-to-severe chronic cancer pain: a multicenter, double-blind, non-inferiority randomized controlled trial]. It reports Conclusion: Once-daily hydromorphone ER was non-inferior to twice-daily oxycodone CR for managing moderate-to-severe chronic cancer pain, with similar safety profiles and no statistically significant difference in satisfaction scores, providing an effective therapeutic option with a simplified dosing regimen.

What the study was

Study design
Randomized controlled trial
Population
Human participants
Category
Other
Maturity
Validated
Journal
Zhonghua yi xue za zhi

Why it surfaced

Randomized controlled trial; conservative rapid-triage score based on PubMed title, publication type, and abstract.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.